Ensure accurate and reliable patient test results with our new online interlaboratory data management programme, Acusera 24.7 Live Online.  Providing access to a range of customisable charts and peer group statistics generated from over 20,000 laboratory participants, Acusera 24.7 Live Online is the most comprehensive data management package in the world.

The analytical capabilities of Acusera 24.7 Live Online coupled with the superior quality and flexibility of the Acusera control range will revolutionise your laboratories workflow.

Acusera

• Third party controls for independent performance monitoring

• Multi-analyte controls enabling effective consolidation

• 100% human controls for immunoassay purposes

• Unrivalled stability helping to reduce waste and costs

Acusera 24.7 Live Online

• Online access anytime, anywhere

• Fully customisable charts and reports

• Peer group statistics uniquely updated every 24 hours

• Connects direct to your LIS for automatic data entry

Click here to learn more
Read more

The VACUETTE TUBE-TOUCH is a safety product of the newest generation with an automated activation of the protective shield. This product is a further development of the already existing VACUETTE PREMIUM Safety Needle System. It was developed in close collaboration with users. The result is the VACUETTE TUBE-TOUCH Holder. The new name vividly captures the product’s functional capabilities. The safety mechanism is activated by placing the tube in the holder. In this way, needlestick injuries are automatically avoided. Apart from being easy to use, the VACUETTE TUBE-TOUCH is characterized by its newly designed protective shield, which is freely movable upon activation. Graduation marks have been added to the protective shield in order to easily demonstrate the position of the needle in the vein for the user. These marks show how far the needle is located in the vein. During removal of the needle from the vein, the protective shield automatically encloses the needle making the product practical, simple and safe. This product will be introduced this year in July at the AACC in Houston. Stand 4511.
Read more

A new series of reagent kits is specifically designed for in vitro diagnostic use in conjunction with mass spectrometry instrumentation for clinical analysis. The first kit is focused on vitamin D analysis and is CE marked to meet European regulatory requirements. Highly selective and sensitive, MS provides routine diagnostic testing laboratories in Europe with the ability to quantitate multiple trace level compounds in a single analysis with high confidence in the results. The first kit in the new SCIEX IVD-MS portfolio to harness this advanced technology for routine clinical applications is the SCIEX IVD-MS Kit for 25-OH Vitamin D Analysis.  This kit is designed to help clinicians make diagnoses of vitamin D deficiencies, with the ability to quantitate both 25-OH-Vitamin D2 and 25-OH-Vitamin D3 in a single run. Adequate levels of vitamin D have been known for decades to be essential for strong bones.  Recent research has linked vitamin D to be important in the prevention of multiple common and serious diseases, such as type 1 diabetes, cancer and heart disease. The new SCIEX IVD-MS kits work with the AB SCIEX 3200MD CE-IVD series of MS systems – including the API 3200MD and 3200MD QTRAP LC/MS/MS systems – which the company launched recently in Europe.
Read more

For the measurement of fibrinogen concentration in plasma, Fibrinogen by BioSystems is a turbidimetry liquid bireagent method which is calibrated with a multipoint curve (lyophilized standard) and controlled with a lyophilized control plasma. Fibrinogen is a protein that is essential for blood clot formation. It is produced by the liver and released into the circulation as needed along with several other clotting factors. The concentrations of fibrinogen are increased in case of diabetes, obesity and inflammatory syndromes and are decreased in case of disseminated intravascular coagulation (DIC), fibrinolysis and genetic deficiency. In addition, elevated concentrations of fibrinogen can be involved in the pathogenicity of different cardiovascular thrombotic events. In recent years, a large number of prospective studies have shown that the fibrinogen concentration is a predictor of a variety of cardiovascular events, including stroke, myocardial infarction, leg ischemia (in arterial disease) and postsurgical arterial re-occlusion.

Read more

Designed for use on the Liaison Iam instrument, the Iam Parvo assay is a highly sensitive, rapid quantitative molecular assay for Parvovirus B19 diagnosis.  Parvovirus B19 (B19V) infection is common and occurs worldwide, with epidemics following a 3-4 year cycle.  The virus is typically acquired in childhood when it causes the mild, self-limiting rash illness erythema infectiosum (commonly known as ‘slapped cheek’ or ‘fifth disease’).  It is transmitted through respiratory droplets and can vary in severity from asymptomatic to life-threatening illness.  B19V infection during pregnancy can have severe consequences. The infection can transfer from mother to fetus across the placenta and may cause fetal death or poor outcomes (including severe neurological disease) in surviving babies.  B19V is also problematic in immunocompromized patients and is the leading cause of pure red cell aplasia in AIDS patients.  In individuals with sickle cell anemia, B19V infection can result in transient aplastic crisis (TAC).  Chronic B19V infection can lead to persistent and severe anemia and is also associated with conditions such as arthropathy, glomerulonephritis and neurological disease. Calibrated against the WHO standard for B19V, Iam Parvo provides exceptional time-to-result benefits when compared to PCR, with equivalent specificity. The Liaison Iam instrument uses DiaSorin’s proprietary Q-LAMP technology.

Read more